Research integrity and pharmaceutical industry sponsorship

Medical Journal of Australia

Volumn 182, Issue 11, 2005, Pages 549-550

  Gøtzsche, Peter C ^a  

^a Nordic Cochrane Centre   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR;

ARTERY THROMBOSIS; CLINICAL TRIAL; DRUG INDUSTRY; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; HYPERTENSION; MEDICAL RESEARCH; PROFESSIONAL MISCONDUCT; RESEARCH ETHICS; SELF REPORT;

EID: 20444477938     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06807.x     Document Type: Editorial

References (11)

1. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454-465.
2. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999; 282: 1752-1759.
3. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002; 190: 583-592.
4. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928.
5. Chan A-W, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 2004; 291: 2457-2465.
6. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-2288.
7. Jüni P, Nartey L, Reichenbach S, et a.l Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-2029.
8. Henry DA, Kerridge IH, Hill SR, et al. Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. Med J Aust 2005; 182: 557-560.
9. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Available at: http://www.icmje.org/clin_trial.pdf (accessed Apr 2005).
10. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials 1996; 17: 285-290.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.